pre-IPO PHARMA

COMPANY OVERVIEW

Chondrial Therapeutics is an emerging biotechnology company focused on the treatment of rare mitochondrial diseases. Chondrial’s lead compound is CTI-1601, which the Company is developing as a potential treatment for Friedreich’s Ataxia. CTI-1601 is designed to deliver the frataxin protein to the mitochondria of patients with Friedreich’s Ataxia, who, due to a genetic abnormality, are unable to produce this essential protein.


LOCATION

  • Bala Cynwyd, PA, USA

  • THERAPEUTIC AREAS

  • Rare Diseases

  • WEBSITE

    https://chondrialtherapeutics.com


    CAREER WEBSITE


    SOCIAL MEDIA


    INVESTORS

    deerfield-management


    PRESS RELEASES


    May 29, 2020

    Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics


    Dec 18, 2019

    Chondrial Therapeutics Announces Dosing of First Patients in Phase 1 Clinical Program of CTI-1601 for Treatment of Friedreich’s Ataxia


    Dec 18, 2019

    Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement


    Feb 6, 2017

    Chondrial Therapeutics Secures Up to $22.6 Million in Series A Financing and Licenses Novel Technology for the Treatment of Friedreich's Ataxia


    For More Press Releases


    Google Analytics Alternative